<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1610600" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Familial cold autoinflammatory syndrome</z:e> (FCAS) and the related autoinflammatory disorders, <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> and <z:hpo ids='HP_0003623'>neonatal onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, are characterized by mutations in the CIAS1 gene that encodes cryopyrin, an adaptor protein involved in activation of IL-converting enzyme/caspase-1 </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations in cryopyrin are hypothesized to result in abnormal secretion of caspase-1-dependent proinflammatory cytokines, IL-1beta and IL-18 </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we examined cytokine secretion in PBMCs from FCAS patients and found a marked hyperresponsiveness of both IL-1beta and IL-18 secretion to LPS stimulation, but no evidence of increased basal secretion of these cytokines, or alterations in basal or stimulated pro-IL-1beta levels </plain></SENT>
<SENT sid="3" pm="."><plain>VX-765, an orally active IL-converting enzyme/caspase-1 inhibitor, blocked IL-1beta secretion with equal potency in LPS-stimulated cells from FCAS and control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>These results further link mutations in cryopyrin with abnormal caspase-1 activation, and support the clinical testing of caspase-1 inhibitors such as VX-765 in autoinflammatory disorders </plain></SENT>
</text></document>